Glyscend taps CEO to lead oral obesity, type 2 diabetes candidate; Ex-Travecta chief bounces back after company shutdown
As a new wave of type 2 diabetes and obesity drugs takes the industry by storm, Glyscend Therapeutics has tapped a new CEO to lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
